Evidence map›Paper›PMID 34681840›Full record

ArticleInternational journal of molecular sciences2021

PD-L1 Status in Gastric Cancers, Association with the Transcriptional, Growth Factors, AKT/mTOR Components Change, and Autophagy Initiation.

Liudmila Spirina, Alexandra Avgustinovich, Sergei Afanas'ev, Maxim Volkov, Alexey Dobrodeev, Olga Cheremisina, Dmitry Kostromitsky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. The influence ofFrontiers in immunology · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Liudmila SpirinaCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.ORCID 0000-0002-5269-736X
Alexandra AvgustinovichCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.
Sergei Afanas'evCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.
Maxim VolkovCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.
Alexey DobrodeevCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.
Olga CheremisinaCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.
Dmitry KostromitskyCancer Research Institute, Tomsk National Research Medical Center, 634000 Tomsk, Russia.
Tomsk National Research Medical Center · RUSiberian State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe programmed death receptor ligand 1 (PD-L1) immunohistochemistry (IHC) assay is a widely used selection method for pembrolizumab treatment in gastric cancer (GC) patients. PD-L1 is the main regulator of immunity in oncogenesis. MATERIAL AND

methodsThe study included 38 patients with GC. The combined treatment consisted of neoadjuvant FOLFOX6, or FLOT, chemotherapy and surgery. PD-L1 + tumor status was recorded in 12 patients (CPS > 5), with a negative status recorded in 26 patients. RT-PCR determined the expression of molecular markers. The level of LC3B protein was detected by Western Blotting analysis.

resultsAn overexpression of PD-1, PD-L2 in the tumor is associated with AKT/mTOR mRNA profile change and autophagy initiation in IHC PD-L1 positive GCs. NACT influences these biological features, modifying the expression of AKT/mTOR components and autophagic flux. In PD-L1 positive cancers, the effect of NACT and molecular markers rearrangements are essential compared to the PD-L1 negative cancers.

conclusionThe IHC PD-L1 status in gastric cancers is the significant marker of cancer progression, recovering the multiple inner mechanisms of cancer spreading and leading to ineffective therapy. Autophagy induction and angiogenesis are found in PD-L1 positive gastric cancers.

Indexed as

AdultAutophagyB7-H1 AntigenBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryIntercellular Signaling Peptides and ProteinsMaleMicrotubule-Associated ProteinsMiddle AgedProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktSignal TransductionB7-H1 AntigenBiomarkers, TumorCD274 protein, humanIntercellular Signaling Peptides and ProteinsMAP1LC3B protein, humanMicrotubule-Associated ProteinsMTOR protein, humanPDCD1LG2 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesTranscription FactorsAKT/mTOR componentgastric cancersgrowth factorsLC3BPD-L1transcriptional factors

Identifiers

PMID34681840
PMCPMC8539424
OpenAlexW3206759509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.